Next Article in Journal
Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan
Next Article in Special Issue
The Role of Ultrasound Guided Sampling Procedures in the Diagnosis of Pelvic Masses: A Narrative Review of the Literature
Previous Article in Journal
Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care
Previous Article in Special Issue
Acute Mesenteric Vein Thrombosis in a Pregnant Patient at 10 Weeks Gestation: A Case Report
 
 
Interesting Images

18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab

1
Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France
2
Laboratoire d’Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France
3
Department of Medical Oncology, Institut Curie, PSL Research University, 92210 Saint-Cloud, France
4
Department of Medical Imaging, Institut Curie, 92210 Saint-Cloud, France
5
Circulating Tumor Biomarkers Laboratory, SiRIC, Institut Curie, PSL Research University, 75005 Paris, France
6
Department of Surgery, Institut Curie, PSL Research University, 92210 Saint-Cloud, France
*
Author to whom correspondence should be addressed.
Academic Editor: Manuela Ludovisi
Diagnostics 2021, 11(8), 1353; https://doi.org/10.3390/diagnostics11081353
Received: 8 July 2021 / Revised: 24 July 2021 / Accepted: 25 July 2021 / Published: 28 July 2021
(This article belongs to the Special Issue Imaging of Gynecological Disease)
Dostarlimab is an immune checkpoint inhibitor (ICI) targeting the Programmed-Death-1 (PD-1) co-receptor, recently approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a novel therapy for recurrent or advanced endometrial cancer. We report the case of a 64-year-old woman, experiencing vaginal recurrence with microsatellite instability high/hypermutated of a FIGO stage IA grade 2 endometrial endometrioid adenocarcinoma. She received preoperative chemotherapy with four cycles of carboplatin plus paclitaxel, with stable disease on pelvic magnetic resonance imaging (MRI) and fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). Dostarlimab (500 mg intravenously every 3 weeks) was then introduced. The subsequent evaluation after three perfusions demonstrated a complete metabolic response on 18F-FDG PET/CT according to immunotherapy-modified PET response criteria in solid tumors (imPERCIST) criteria, then confirmed by MRI according to immune response evaluation criteria in solid tumors (iRECIST). This clinical description suggests that 18F-FDG PET/CT might take place among available tools for guiding the preoperative management for recurrent endometrial cancer patients receiving dostarlimab immunotherapy that should be further explored through clinical trials. View Full-Text
Keywords: 18F-FDG PET/CT; endometrial adenocarcinoma; dostarlimab; immunotherapy; tumor response; microsatellite instability high/hypermutated 18F-FDG PET/CT; endometrial adenocarcinoma; dostarlimab; immunotherapy; tumor response; microsatellite instability high/hypermutated
Show Figures

Figure 1

MDPI and ACS Style

Seban, R.-D.; Donnadieu, A.; Journo, G.; Bidard, F.-C.; Richard, C.; Rouzier, R.; Champion, L. 18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. Diagnostics 2021, 11, 1353. https://doi.org/10.3390/diagnostics11081353

AMA Style

Seban R-D, Donnadieu A, Journo G, Bidard F-C, Richard C, Rouzier R, Champion L. 18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. Diagnostics. 2021; 11(8):1353. https://doi.org/10.3390/diagnostics11081353

Chicago/Turabian Style

Seban, Romain-David, Anne Donnadieu, Gabrielle Journo, Francois-Clement Bidard, Capucine Richard, Roman Rouzier, and Laurence Champion. 2021. "18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab" Diagnostics 11, no. 8: 1353. https://doi.org/10.3390/diagnostics11081353

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop